Clinical trial NCT02048488: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
Official title: A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Solid Tumors
Lymphomas
Keywords: non small cell lung cancer
NSCLC
Anaplastic lymphoma kinase
ALK tyrosine kinase receptor
ALK+
TRK+
ALK inhibitor
TRK inhibitor
tropomyosin receptor kinase
TRKA
TRKB
TRKC
advanced malignancy
Lead sponsor: Tesaro, Inc.
Sponsor class: INDUSTRY
First posted: 2014-01-29
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including:

1. Anaplastic lymphoma kinase (ALK)
2. The tropomyosin-related kinases TRKA, TRKB, and TRKC

This is a sequential, open-label, non-randomized study with dose escalation in Phase 1, followed by expansion at a recommended phase 2 dose.


Eligibility criteria: Inclusion Criteria:

* To be considered eligible to participate in this study, all of the following requirements must be met:

  1. Patients in Phase 1 must have metastatic or locally advanced solid tumors who have failed to respond to standard therapy
  2. All patients must have confirmation of either ALK positive or TRK positive status.
  3. Patients in Phase 1 will not be required to have measurable disease. All patients in Phase 2a will be required to have measurable disease by RECIST.
  4. All patients enrolled in this study must have tumor tissue available.
  5. Patient (male or female) must be ≥ 18 years of age (except where age of majority is 16 years in a particular country, such as the United Kingdom).
  6. Patient must have performance status ≤2 on the ECOG Performance Scale.
  7. Patient must have an estimated life expectancy of at least 3 months.
  8. Patients must have adequate organ function.
  9. For patients previously treated with myelosuppressive therapy, at least 3 weeks must have elapsed and toxicity must have recovered to grade 1 or baseline. Non-myelosuppressive therapy patients must have recovered from all treatment-related toxicities. Fourteen days must have elapsed since palliative radiation for bone metastasis.
  10. Female patients of childbearing potential must have a negative serum pregnancy test and use adequate birth control for the duration of study participation and for 3 months after the last dose of study drug.
  11. The patient or his or her legal representative must be able to read, understand, and provide signed informed consent.
  12. Patient is able to understand the study procedures and agrees to participate in the study by giving written informed consent.

Exclusion Criteria:

* Patients will not be deemed eligible for entry into this study if any of the following criteria are met:

  1. Patient has leukemia.
  2. Patient is a pregnant or lactating female.
  3. Patient has uncontrolled congestive heart failure, angina, or has had a myocardial infarction in the preceding 3 months.
  4. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, atrial fibrillation of any grade, or QTc interval \>450 msec.
  5. Patients with risk factors for Torsade de point and patients receiving concomitant medication with QT-prolonging medicines.
  6. Patient has an uncontrolled concurrent medical condition or disease.
  7. Patient has undergone bone marrow or stem cell transplantation in the past 6 months.
  8. Patient has a known hypersensitivity to the components of TSR-011 or the excipients.
  9. Patient has active or uncontrolled infection.
  10. Patient has a known psychiatric or substance abuse disorder.
  11. Patient has active second primary malignancy.
  12. Patient is observed to have a clinically active central nervous system (CNS) metastases or carcinomatous meningitis.
  13. Patient has any other severe concurrent disease which, in the judgment of the Investigator, would preclude study participation.
  14. Patient is known to be HIV positive or who has an AIDS-related illness.
  15. Patient has a known history of or active (treated or not) Hepatitis B or C.
  16. Patient has presence of ascites causing significant symptoms.
  17. A patient must stop taking any prescription, over-the-counter, or herbal remedy known to be an inhibitor or inducer of CYP3A4/5.

Primary outcomes:
measure: Incidence of Adverse Events (AEs)
timeFrame: Approximately 2 years
Secondary outcomes:
measure: Area Under the Concentration-Time Curve (AUC)
timeFrame: Day 1: 0-24 hrs after first dose; pre-dose on days 8 & 15; day 29: 0-24 hours
measure: Maximum Tolerated Dose (MTD)
timeFrame: 28 days after first dose
measure: Response Rate (RR)
timeFrame: approximately 2 years
measure: Dose limiting toxicity (DLT)
timeFrame: 28 days after first dose
measure: Progression Free Survival (PFS)
timeFrame: approximately 2 years
measure: Recommended Phase 2 Dose (RP2D)
timeFrame: approximately 2 years
Other outcomes:
Locations:
city: Goodyear
country: United States
state: Arizona
city: Scottsdale
country: United States
state: Arizona
city: Los Angeles
country: United States
state: California
city: Nashville
country: United States
state: Tennessee
city: Norfolk
country: United States
state: Virginia
city: Spokane
country: United States
state: Washington
city: Warsaw
country: Poland
state: Mazowieckie
city: Gdansk
country: Poland
state: Pomorskie
city: Olsztyn
country: Poland
state: Warminsko-Mazurskie
city: Poznan
country: Poland
state: Wielkopolskie
city: Madrid
country: Spain
city: Santiago de Compostela
country: Spain
city: Tainan City
country: Taiwan
city: Taipei
country: Taiwan
city: London
country: United Kingdom
Study officials:
affiliation: Tesaro, Inc.
name: Dmitri Bobilev, MD
role: STUDY_DIRECTOR
References:
citation: Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeno J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. Br J Cancer. 2019 Jul;121(2):131-138. doi: 10.1038/s41416-019-0503-9. Epub 2019 Jun 20.